Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01318499 · ClinicalTrials.gov registry record · Phase 2
Nepafenac 0.3% Two Study
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,342
- Enrollment target
NCT01318499: Completed Phase 2 study, sponsored by Alcon Research.
NCT01318499 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 1,342 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (909% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01318499, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,342 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
Primary Outcome
Ocular inflammation was assessed by the investigator during slit lamp examination. Aqueous cells were scored on a 5-unit scale from 0 (none) to 4 (\> 30 cells), and aqueous flare (protein escaping from dilated vessels) was scored on a 4-unit scale from 0 (no visible flare when compared with the normal eye) to 3 (severe - very dense flare). To be considered cured, the patient must have had a score of 0 for both aqueous cells and aqueous flare.
Interventions
- DRUG Nepafenac Ophthalmic Suspension, 0.3%
- DRUG Nepafenac Ophthalmic Suspension, 0.1%
- OTHER Nepafenac Vehicle 0.3%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,342 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
What the finished NCT01318499 record still lists
NCT01318499 is an interventional study that assigns participants to a tested intervention. Its 1,342 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (909% higher).
The record links to 0 conditions, and to 3 interventions - of which Nepafenac Ophthalmic Suspension, 0.3% is the first listed.
NCT01318499 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01318499 about?
NCT01318499 is a clinical study titled "Nepafenac 0.3% Two Study". The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
What is the current status of trial NCT01318499?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,342 participants. The study started on 2011-03. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01318499?
The interventions under investigation include: Nepafenac Ophthalmic Suspension, 0.3% (DRUG), Nepafenac Ophthalmic Suspension, 0.1% (DRUG), Nepafenac Vehicle 0.3% (OTHER).
Who is sponsoring clinical trial NCT01318499?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01318499's enrollment target sits among peer trials
1,342 13th of 2000 higher than 1,988 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06731608 · 1,344 participants · NA
OsteoPorotic fracTure preventION System (OPTIONS) Research Study
- NCT06972056 · 1,335 participants · Phase 4
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia